Navigation Links
Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System
Date:3/4/2009

ST. LOUIS, March 4 /PRNewswire/ -- CMS Software, part of the Elekta Group and leader in radiation treatment planning and workflow management solutions, today announced that Oregon Health & Science University (OHSU) Knight Cancer Institute has purchased Monaco, the next-generation Intensity Modulated Radiotherapy (IMRT) treatment planning system.

Featuring biological modeling, constrained optimization, sensitivity analysis and Monte Carlo dose calculation algorithms, Monaco represents a new approach to IMRT planning, including a sophisticated set of tools to make the radiotherapy planning process easier, more straightforward and more clinically reliable.

"The OHSU Department of Radiation Medicine is excited to offer its patients new technology that comes with the purchase of Monaco," says Wolfram Laub, Ph.D., and Associate-Director of Medical Physics at OHSU. "The department has acquired multiple new technologies within the past few years and is a state-of-the-art facility. This recent purchase underlines OHSUs commitment to providing patients access to cutting-edge radiation therapy treatment."

As the clinic continues to adopt advanced treatment planning technologies, they intend to review the soon-to-be-released Volumetric Modulated Arc Therapy (VMAT)* planning functionality in Monaco. With the addition of VMAT to Monaco, clinicians will have additional benefits including:

  • Simultaneous optimization of multiple non-coplanar arcs, which allows flexibility when planning with one or more arcs.
  • Monte Carlo dose engine allows continuous arc calculation rather than being limited to dosing approximations with discrete gantry positions.
  • Biologically based constrained optimization, which enables better target dose conformity and normal tissue sparing.

Developed in collaboration with leading academic healthcare institutions, Elekta's comprehensive VMAT solution, with 3D volumetric imaging and advanced treatment planning algorithms, allows more precise dose distribution and faster treatment delivery. Future developments include creating more efficacious and efficient approaches for clinicians to deliver patient care. For additional information, visit elekta.com/vmat.

*Monaco VMAT functionality is a works-in-progress.

About CMS Software

CMS Software is part of the Elekta Group, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to help in the cure of cancer patients with curable disease and to improve the quality of life of those patients with metastatic disease, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

With more than 2,500 employees globally, Elekta's corporate headquarters are located in Stockholm, Sweden and the company is listed on the Nordic Exchange under the ticker EKTAb. More information can be found at www.cmsrtp.com and www.elekta.com.

About the OHSU Cancer Institute

The OHSU Cancer Institute is the only National Cancer Institute-designated center between Sacramento and Seattle. It comprises some 200 clinical researchers, basic scientists and population scientists who work together to translate scientific discoveries into longer and better lives for Oregon's cancer patients. In the lab, basic scientists examine cancer cells and normal cells to uncover molecular abnormalities that cause the disease. This basic science informs more than 300 clinical trials conducted at the OHSU Cancer Institute. Additional information may be found at www.ohsucancer.com.

About OHSU

Oregon Health & Science University is the state's only health and research university, and Oregon's only academic health center. OHSU is Portland's largest employer and the fourth largest in Oregon (excluding government), with 12,400 employees. OHSUs size contributes to its ability to provide many services and community support activities not found anywhere else in the state. It serves patients from every corner of the state, and is a conduit for learning for more than 3,400 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to every county in the state.


'/>"/>
SOURCE CMS Software
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Phlo Affiliate Reports Expanded Coverage to Oregon Border
2. Assured Pharmacy Consolidates Portland, Oregon Pharmacy
3. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
4. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
5. Oregon theory may help design tomorrows sustainable polymer
6. Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
9. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):